NCT07431255 · NOT YET RECRUITING
Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease
This study tests an AI model that tries to generate one type of brain scan image from another — specifically, creating a metabolic FDG PET image using only an amyloid PET scan and an MRI. No new patients are enrolled and no new procedures are done; researchers are working entirely with anonymized scan data already collected. The phase is unspecified, making this more of a technical feasibility study than a clinical trial in the traditional sense.
You may qualify if
- Age ≥ 50 years at the time of imaging.
- Clinically indicated amyloid PET scan performed with Florbetaben or Flutemetamol between January 1, 2025 and December 31, 2025.
- Availability of paired structural MRI (3D T1-weighted) and real [18F]FDG PET scan acquired within ±6 months of the amyloid PET.
- All three imaging modalities (Amyloid PET, FDG PET, MRI) are of sufficient technical quality for co-registration and quantitative analysis.
You're excluded if
- Presence of other major neurological disorders that may confound FDG metabolism (e.g., Parkinson's disease, frontotemporal dementia, brain tumor, or recent stroke).
- Severe motion artifacts or technical failures in any of the three imaging modalities that prevent reliable co-registration or SUVR calculation.
- Incomplete or irreversibly corrupted DICOM data preventing anonymization or conversion to analysis-ready format.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-02-24